ACHV Stock Price, Achieve Life Sciences Quote, Chart

Market Summary

USD5.00-0.07

Market Closed

-1.38%

ACHV Stock Price

View Fullscreen

ACHV RSI Chart

ACHV Valuation

Market Cap

171.7M

Price/Earnings (Trailing)

-6.28

Price/Sales (Trailing)

30.73

EV/EBITDA

-3.97

Price/Free Cashflow

-7.99

ACHV Price/Sales (Trailing)

ACHV Profitability

EBT Margin

-589.00%

Return on Equity

-55.29%

Return on Assets

-39.04%

Free Cashflow Yield

-12.52%

ACHV Fundamentals

ACHV Revenue

Revenue (TTM)

5.1M

ACHV Earnings

Earnings (TTM)

-27.3M

Earnings Growth (Yr)

27.71%

Earnings Growth (Qtr)

-18.28%

Breaking Down ACHV Revenue

Last 7 days

8.5%

Last 30 days

9.4%

Last 90 days

15.7%

Trailing 12 Months

-30.1%

How does ACHV drawdown profile look like?

ACHV Financial Health

Current Ratio

3.29

Debt/Equity

0.33

Debt/Cashflow

-1.33

ACHV Investor Care

Shares Dilution (1Y)

90.35%

Diluted EPS (TTM)

-1.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2016	19.7M	17.8M	11.1M	5.1M
2015	16.8M	15.9M	17.8M	18.2M
2014	36.5M	35.1M	30.1M	27.1M
2013	23.9M	27.8M	31.1M	29.9M
2012	5.6M	6.2M	11.6M	20.1M
2011	10.1M	10.3M	6.6M	5.5M
2010	0	21.6M	17.6M	13.6M
2009	0	0	0	25.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Achieve Life Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	jacobs cindy	acquired	-	-	16,250	president & cmo
Apr 19, 2024	jacobs cindy	sold (taxes)	-17,846	4.51	-3,957	president & cmo
Apr 19, 2024	wan jerry	acquired	-	-	5,625	principal accounting officer
Apr 19, 2024	wan jerry	sold (taxes)	-10,147	4.51	-2,250	principal accounting officer
Apr 19, 2024	stewart richard alistair	acquired	-	-	22,500	executive chairman
Apr 19, 2024	stewart richard alistair	sold (taxes)	-45,663	4.51	-10,125	executive chairman
Apr 19, 2024	bencich john	acquired	-	-	25,000	ceo
Apr 19, 2024	bencich john	sold (taxes)	-27,456	4.51	-6,088	ceo
Mar 04, 2024	stewart richard alistair	bought	45,850	4.585	10,000	executive chairman
Mar 04, 2024	bencich john	bought	45,850	4.585	10,000	ceo

Which funds bought or sold ACHV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	unchanged	-	1,062	11,362	-%
May 15, 2024	Sofinnova Investments, Inc.	new	-	6,900,360	6,900,360	0.38%
May 15, 2024	Nantahala Capital Management, LLC	new	-	2,972,430	2,972,430	0.17%
May 15, 2024	Alyeska Investment Group, L.P.	new	-	2,140,700	2,140,700	0.01%
May 15, 2024	J. Goldman & Co LP	reduced	-63.63	-166,533	111,571	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	880,085	880,085	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	23.00	23.00	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	100,981	100,981	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	15.86	3,107	14,280	-%
May 15, 2024	STATE STREET CORP	reduced	-12.79	-9,905	250,957	-%

Are Funds Buying or Selling ACHV?

Are funds buying ACHV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACHV

No. of Funds

Unveiling Achieve Life Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	franklin resources inc	12.0%	4,365,755	SC 13G
Feb 27, 2024	callahan patrick j. iii	9.9%	2,167,439	SC 13G
Jun 02, 2023	contrarian alpha, lp	9.2%	1,978,377	SC 13G/A
Apr 18, 2023	dialectic capital management, lp	19.68%	3,538,093	SC 13G
Mar 23, 2023	dialectic capital management, lp	19.5%	3,494,000	SC 13D/A
Mar 06, 2023	dialectic capital management, lp	19.5%	3,494,000	SC 13D/A
Feb 13, 2023	francis capital management, llc	3.6%	648,648	SC 13G/A
Feb 10, 2023	svb financial group	8.8%	1,716,764	SC 13G/A
Jan 20, 2023	dialectic capital management, lp	19.5%	3,494,000	SC 13D
Nov 28, 2022	contrarian achieve spv, lp	369%	1,318,918	SC 13G

Recent SEC filings of Achieve Life Sciences Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	SC 13G	Major Ownership Report
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 06, 2024	EFFECT	EFFECT
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	S-3	S-3
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading

Peers (Alternatives to Achieve Life Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Achieve Life Sciences Inc News

Latest updates

Achieve Life Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4	2012Q3	2012Q2	2012Q1	2011Q4
Revenue	-	-	-	2,122,000	2,940,000	6,024,000	6,737,000	4,025,000	1,374,000	5,653,000	4,803,000	4,929,000	11,731,000	8,604,000	9,862,000	6,340,000	5,076,000	9,780,000	6,570,000	2,429,000	1,316,000	1,236,000
Operating Expenses	-	-	-	-	7,372,000	9,503,000	11,428,000	-	6,371,000	-	12,045,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	261.5%	70.00	19.00	24.00	29.00	21.00	30.00	24.00	34.00	41.00	48.00	38.00	46.00	34.00	40.00	28.00	16.00	17.00	21.00	11.00	15.00	15.00
Current Assets	298.7%	68.00	17.00	22.00	26.00	18.00	27.00	21.00	31.00	38.00	45.00	35.00	42.00	30.00	37.00	24.00	13.00	13.00	17.00	8.00	11.00	11.00
Cash Equivalents	328.4%	66.00	16.00	20.00	25.00	17.00	25.00	18.00	29.00	36.00	43.00	33.00	42.00	30.00	36.00	22.00	12.00	12.00	17.00	7.00	10.00	7.00
Net PPE	-100.0%	-	0.00	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-1.2%	21.00	21.00	20.00	19.00	20.00	22.00	23.00	21.00	19.00	19.00	3.00	5.00	4.00	3.00	2.00	2.00	2.00	3.00	3.00	3.00	4.00
Current Liabilities	-1.2%	21.00	21.00	4.00	3.00	20.00	22.00	7.00	5.00	4.00	5.00	3.00	5.00	4.00	3.00	2.00	2.00	2.00	3.00	3.00	3.00	4.00
Long Term Debt	-	-	-	16.00	16.00	-	-	16.00	15.00	15.00	15.00	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	2.9%	17.00	17.00	-	-	16.00	16.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	16.00	16.00	-	-	16.00	15.00	15.00	15.00	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	3515.5%	49.00	-1.45	4.00	10.00	0.00	8.00	1.00	13.00	21.00	28.00	35.00	41.00	30.00	37.00	26.00	15.00	15.00	18.00	8.00	12.00	10.00
Retained Earnings	-3.9%	-172	-165	-160	-153	-144	-135	-124	-111	-101	-93.59	-86.43	-79.70	-68.43	-60.43	-55.71	-51.95	-49.02	-45.70	-42.51	-38.84	-31.29
Additional Paid-In Capital	34.9%	222	164	164	163	145	144	126	125	123	122	121	121	98.00	98.00	81.00	66.00	64.00	64.00	51.00	50.00	41.00
Shares Outstanding	61.8%	34.00	21.00	21.00	21.00	18.00	18.00	10.00	10.00	9.00	8.00	8.00	7.00	6.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	91.00	-	-	-	47.00	-	-	-	85.00	-	-	-	15.00	-	-	-	15.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-21.0%	-5,300	-4,379	-5,100	-6,700	-8,300	-11,143	-11,307	-8,340	-6,779	-5,218	-8,694	-9,076	-6,452	-2,480	-4,335	-2,198	-4,461	-3,414	-3,072	-3,841	-4,889
Share Based Compensation	13657.9%	1,288	-9.50	1,174	1,189	1,085	778	829	840	823	494	530	621	542	395	281	308	302	284	310	317	290
Cashflow From Investing	100.0%	-	-6.00	-	-	-	-	-	-	-	-	-	-	-	-	-3.00	-12.00	-2.00	-1.00	-	2,347	2,690
Cashflow From Financing	-	56,110	-	-	15,231	47.00	17,713	126	1,381	95.00	14,928	8.00	21,438	236	15,940	14,620	2,167	-47.00	12,703	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ACHV Income Statement

2024-03-31

Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
EXPENSES
Research and development	$ 2,799	$ 5,534
General and administrative	3,183	3,044
Total operating expenses	5,982	8,578
OTHER INCOME (EXPENSE)
Interest income	368	162
Interest expense [note 7]	(813)	(573)
Change in fair value of contingent consideration [note 5 and note 6]	(52)
Other expense	(15)	(3)
Total other expense	(512)	(414)
Net loss and comprehensive loss	$ (6,494)	$ (8,992)
Basic net loss per common share [note 8[d]]	$ (0.26)	$ (0.50)
Diluted net loss per common share [note 8[d]]	$ (0.26)	$ (0.50)
Weighted average shares used in computation of basic net loss per common share [note 8[d]]	25,048,134	17,917,769
Weighted average shares used in computation of diluted net loss per common share [note 8[d]]	25,048,134	17,917,769

ACHV Balance Sheet

2024-03-31

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents [note 6]	$ 66,398	$ 15,546
Grant receivable [note 3]		111
Prepaid expenses and other assets	1,311	1,325
Total current assets	67,709	16,982
Right-of-use assets [note 9]	51	66
Other assets and restricted cash [note 6]	94	92
License agreement [note 4 and note 5]	1,141	1,197
Goodwill	1,034	1,034
Total assets	70,029	19,371
Current liabilities:
Accounts payable	373	618
Accrued liabilities other	1,037	351
Contingent consideration [note 5 and note 6]	580	528
Accrued clinical liabilities	525	280
Accrued compensation	864	2,311
Current portion of long-term obligations [note 9]	53	63
Convertible debt [note 6 and note 7]	17,141	16,662
Total current liabilities	20,573	20,813
Long-term obligations [note 9]		6
Total liabilities	20,573	20,819
Commitments and contingencies [note 9]
Stockholders' equity:
Common stock, $0.001 par value, 150,000,000 shares authorized, 34,251,911 issued and outstanding at March 31, 2024 and 21,165,760 issued and outstanding at December 31, 2023	103	90
Additional paid-in capital	221,594	164,209
Accumulated deficit	(172,245)	(165,751)
Accumulated other comprehensive income	4	4
Total stockholders' equity	49,456	(1,448)
Total liabilities and stockholders' equity	70,029	19,371
Series A Convertible Preferred Stock [Member]
Stockholders' equity:
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]
Stockholders' equity:
Convertible preferred stock, value

About Achieve Life Sciences Inc

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.

CEO	Mr. John A. Bencich M.B.A.
WEBSITE	achievelifesciences.com
INDUSTRY	Biotechnology
EMPLOYEES	20

Achieve Life Sciences Inc Frequently Asked Questions

What is the ticker symbol for Achieve Life Sciences Inc? What does ACHV stand for in stocks?

ACHV is the stock ticker symbol of Achieve Life Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Achieve Life Sciences Inc (ACHV)?

As of Fri May 17 2024, market cap of Achieve Life Sciences Inc is 171.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACHV stock?

You can check ACHV's fair value in chart for subscribers.

What is the fair value of ACHV stock?

You can check ACHV's fair value in chart for subscribers. The fair value of Achieve Life Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Achieve Life Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACHV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Achieve Life Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether ACHV is over valued or under valued. Whether Achieve Life Sciences Inc is cheap or expensive depends on the assumptions which impact Achieve Life Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACHV.

What is Achieve Life Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ACHV's PE ratio (Price to Earnings) is -6.28 and Price to Sales (PS) ratio is 30.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACHV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Achieve Life Sciences Inc's stock?

In the past 10 years, Achieve Life Sciences Inc has provided -0.524 (multiply by 100 for percentage) rate of return.